NEWPORT BEACH, Calif.–(BUSINESS WIRE)–jCyte Announces Expansion of its Executive Leadership Team with Appointments in Commercial, Clinical and Manufacturing Operations
Author: Business Wire
Kala Pharmaceuticals Announces EYSUVIS™ Now Covered by Express Scripts
WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that Express Scripts,…
Global Dry Eye Medication Market Report 2020-2030 – Major Players are Novartis, Allergan, Otsuka, Santen Pharmaceutical and Auven Therapeutics – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Dry Eye Medication Global Market Report 2020-30: COVID-19 Impact and Recovery” report has been added to ResearchAndMarkets.com’s offering. The global dry eye medication market is expected to decline from $3.8 billion in 20…
Global Eye Health Supplements Market (2020 to 2026) – by Formulation, Indication, Ingredient Type and Region – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Eye Health Supplements Market By Formulation, By Indication, By Ingredient Type, By Region, Industry Analysis and Forecast, 2020 – 2026” report has been added to ResearchAndMarkets.com’s offering. The Global Eye Hea…
GenSight Biologics Announces Publication of Results from LUMEVOQ® Phase I/IIa Clinical Trial REVEAL in BioDrugs
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative dis…
Gyroscope Therapeutics Announces Positive Interim Data from Phase I/II FOCUS Trial of Investigational Gene Therapy GT005
LONDON–(BUSINESS WIRE)–Gyroscope Therapeutics Announces Positive Interim Data from Phase I/II FOCUS Trial of Investigational Gene Therapy GT005.
Gyroscope Therapeutics Announces Positive Interim Data from Phase I/II FOCUS Trial of Investigational Gene Therapy GT005
LONDON–(BUSINESS WIRE)–Gyroscope Therapeutics Announces Positive Interim Data from Phase I/II FOCUS Trial of Investigational Gene Therapy GT005.
Ocular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2021 – Virtual Edition
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, annou…
New Phase III Data Show Genentech’s Faricimab Is the First Investigational Injectable Eye Medicine to Extend Time Between Treatments up to Four Months in Two Leading Causes of Vision Loss, Potentially Reducing Treatment Burden for Patients
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced detailed results from four Phase III studies of its investigational bispecific antibody, faricimab, for the treatment of d…
NextGen® Patient Experience Platform Adopted by Lone Star Circle of Care Network
ATLANTA–(BUSINESS WIRE)—- $NXGN #AmbulatoryHealthcare–Community Health Centers in Texas Improve Patient Engagement with Well-Integrated Capabilities leveraging NextGen® Patient Experience Platform.
Blinded Veterans Association Endorses Bosma Enterprises’ Good Works® Ice Melter
INDIANAPOLIS–(BUSINESS WIRE)–The Blinded Veterans Association (BVA) today announced its endorsement of Bosma Enterprises’ Good Works® Ice Melter. BVA is the nation’s only congressionally chartered Veterans Service Organization (VSO) created for visua…
STAAR Surgical to Report Fourth Quarter and Fiscal Year Results on February 24, 2021
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the…
Global RG 7774 Pipeline Report 2021: Phase II (NCT04265261) of Clinical Trial for Diabetic Retinopathy – Emerging Insight and Market Forecast to 2030 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “RG 7774 – Emerging Insight and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering. This report provides comprehensive insights about an investigational product for Diabetic Retinopathy in 7 …
What Do Doctors Want in 2021? Sixth Annual Predictions Report from Apollo Intelligence Shows Rising Need for Increased Drug Discovery, Along with Lower Drug Costs
WATERTOWN, Mass.–(BUSINESS WIRE)–What do doctors want in 2021? New data from Apollo Intelligence show more interest in drug discovery, lower drug prices, concern for data privacy.
Trefoil Therapeutics Begins Second Phase 2 “STORM” Clinical Trial with Regenerative Treatment for Fuchs Endothelial Corneal Dystrophy
SAN DIEGO–(BUSINESS WIRE)–Trefoil Therapeutics begins second Phase 2 “STORM” clinical trial with regenerative treatment for Fuchs Endothelial Corneal Dystrophy
2021 Global Dry Eye Clinical Trial Pipeline Highlights – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Dry Eye Clinical Trial Pipeline Highlights – 2021” report has been added to ResearchAndMarkets.com’s offering. This report provides the most up-to-date information on key pipeline products in the global Dry Eye mark…
JCRS Publication of Phase II Nepafenac Clinical Trial With Evolute® Sustained Drug Delivery System Demonstrates Significant Post-Op Pain Reduction in Cataract Surgery Patients
AUSTIN, Texas–(BUSINESS WIRE)–Mati Therapeutics Inc. (“Mati”) announced that a peer reviewed manuscript of a Phase II clinical trial evaluating the safety and efficacy of Nepafenac delivered via Mati’s proprietary Evolute® sustained ocular drug deliv…
NextGen Healthcare’s Revenue Cycle Management Services Adopted by Loden Vision Centers
ATLANTA–(BUSINESS WIRE)–Prominent Ophthalmology Centers in Tennessee Increase Payments by 32 Percent Since Implementation Leveraging NextGen® RCM Services.
LENSAR to Present at Two Upcoming Investor Conferences
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that Nick Curtis, Chie…
jCyte Announces Promotion of Dr. Shannon Blalock to Chief Executive Officer
NEWPORT BEACH, Calif.–(BUSINESS WIRE)–jCyte Announces Promotion of Dr. Shannon Blalock to Chief Executive Officer